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Somatic mutations of the KIT gene have been reported in mast cell diseases and gastrointestinal stromal tumours. Recently, they have
also been found in mediastinal and testicular germ cell tumours (TGCTs), particularly in cases with bilateral disease. We screened the
KIT coding sequence (except exon 1) for germline mutations in 240 pedigrees with two or more cases of TGCT. No germline
mutations were found. Exons 10, 11 and 17 of KIT were examined for somatic mutations in 123 TGCT from 93 multiple-case
testicular cancer families. Five somatic mutations were identified; four were missense amino-acid substitutions in exon 17 and one
was a 12bp in-frame deletion in exon 11. Two of seven TGCT from cases with bilateral disease carried KIT mutations compared with
three out of 116 unilateral cases (P¼0.026). The results indicate that somatic KIT mutations are implicated in the development of a
minority of familial as well as sporadic TGCT. They also lend support to the hypothesis that KIT mutations primarily take place during
embryogenesis such that primordial germ cells with KIT mutations are distributed to both testes.
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Testicular germ cell tumours (TGCTs) are the most common
malignancy in males between the age 15 and 45 years (Ferlay et al,
2001). There are several risk factors for TGCT including previously
diagnosed TGCT, undescended testis (UDT) and a family history
of the disease. TGCT has been one of the highest familial relative
risks of any cancer syndrome with reported increased risks of 8–
10-fold to brothers and 4–6-fold to fathers (Forman et al, 1992;
Heimdal et al, 1996). We previously described linkage of familial
testicular cancer to a locus (TGCT1) at Xq27 (Rapley et al, 2000).
This locus was particularly strongly associated with families
characterised by at least one case of bilateral testicular cancer.
The results indicated, however, that only a minority of families are
attributable to this locus and that additional TGCT susceptibility
genes are likely to exist.
The KIT gene encodes a type III transmembrane tyrosine kinase
receptor. KIT is expressed in several cell types where it regulates
primordial germ cell migration, proliferation and apoptosis during
foetal gonad development (Mauduit et al, 1999). KIT has been
shown to be expressed in some TGCT (Strohmeyer et al, 1995;
Bokemeyer et al, 1996) and somatic mutations in KIT have recently
been identified in testicular (Tian et al, 1999) and mediastinal
germ cell tumours (Przygodzki et al, 2002). Mutations have been
reported in a high proportion of patients with bilateral disease, and
in a much smaller proportion of unilateral cases (Looijenga et al,
2003). When both tumours from bilateral cases could be examined,
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sthe same mutation was present in both tumours. Together, these
results suggest that somatic KIT mutations occur early in
embryogenesis, before the primordial germ cells have divided
and migrated to the gonads. As a consequence, primordial germ
cells with KIT mutations are distributed to both testes and hence
KIT mutations are associated with bilateral disease (Looijenga et al,
2003).
Previous studies have indicated that KIT mutations found in
germ cell tumours are somatic. To investigate further the role of
KIT in predisposition to TGCT, and the role of somatic mutations
in familial tumours, we have examined a series of constitutional
and tumour DNAs from patients with TGCTs and a family history
of the disease.
MATERIALS AND METHODS
The International Testicular Cancer Linkage Consortium (ITCLC)
has obtained samples from 326 families with two or more cases of
TGCT (Table 1). For this study, we analysed DNA extracted from
blood lymphocytes (constitutional DNA) from one affected
individual from each of 240 families, for whom the DNA was
most readily available. The pedigree structure for these families is
shown in Table 1. We also examined tumour materials from 123
cases from 93 families; for 15 of these families, the tumour material
only was available and these were therefore not included in the 240
constitutional DNA set (Table 1). Seven tumours were from
patients with bilateral disease, but the tumour material was only
available from one of each pair of tumours arising in these
patients.
Patients donated samples and medical information with full
informed consent and with local or national ethical review board
approval. Information on clinical status including type of TGCT,
age of diagnosis, presence of UDT and laterality of disease was
confirmed by reviewing histological reports and clinical notes.
DNA was prepared from whole blood and from formalin-fixed,
paraffin-embedded tumour sections using standard techniques.
The tumour material was microdissected to minimise contamina-
tion by surrounding normal tissue. Primer sequences for KIT were
designed from the KIT mRNA and genomic sequence (Ensembl
Table 1 Pedigree structure of cases with family history of TGCT used in KIT mutation search
Family type
Pedigrees (by type)
identified by ITCLC
Number of pedigrees analysed
(by type) using constitutional DNA
Number of pedigrees analysed (by type)
using DNA from tumour material
Sib trios 8 5 2
LargeX3 affected cases 31 22 3
Sib pairs 154 106 43 (11)
a
Father/son pairs 52 46 16 (2)
a
Cousin pairs 40 33 14
Uncle/nephew pairs 32 23 13 (2)
a
Grandfather/grandson pairs 4 5 1
Monozygous twins 4 0 0
Great grandfather/great grandson pairs 1 0 1
Total 326 240 93
aNumber in brackets represents pedigrees (by subtype) for which only tumour material was available for analysis, these families are not included in the KIT analysis of
constitutional DNA samples.
Table 2 KIT gene primer pairs
Exon Forward Reverse PCR product size
Exon2a AATAGCAGGGCAGCTTTGTC GTTGGTGCACGTGTATTTGC 358
Exon2b CTTGGCAGGCTCTTCTCAAC CCTTCTAGACCCAGCCAGAA 395
Exon3a GTGCGTGATACATGGAAAGC GTAGGCGCGTTTCACACTTT 397
Exon3b GCTTCTATAGATCCTGCCAAGC AGGTGGATCAACGAGAAGAGA 372
Exon4 GATAGGTTAGCACCATGCTTTG TCTCCCAGACAATCCACCTC 400
Exon5 TGGAGAAGTTAATTGCTGCTATTTT TCATTCATTCAGTGATAACAAAATTC 389
Exon6 GGAAATCAACCAATTGTTTTTG TCGTGGATTTACGGGTTACA 384
Exon7 CCTCAAACAGGCATAGATTTCC AACCACCAAACCACGAAGTC 364
Exon8 TTCTGCCCTTTGAACTTGCT AAAGCCACATGGCTAGAAAAA 386
Exon9 ATGCCACATCCCAAGTGTTT TGACATGGTCAATGTTGGAA 364
Exon10 AACCAAGGTGAAGCTCTGAGAC CTCCTCAACAACCTTCCACTG 384
Exon 10 small ATCCCATCCTGCCAAAGTT CTGTGGGGAGAAAGGGAAA 246
Exon11 TAGCTGGCATGATGTGCATT GGCGCAATTTCACAGAAAAC 397
Exon 11 small AGAGTGCTCTAATGACTGAGACAA AAACAAAGGAAGCCACTGGA 279
Exon12 ATTGCGCCCCTTTTGATAG GTTCAGACATGAGGGCTTCC 392
Exon13 TGCTCAAGCGTAAGTTCCTG GCAAGAGAGAACAACAGTCTGG 335
Exon14a CTCCACATAAGGCTGCTTTT CCCATGAACTGCCTGTCAAC 381
Exon14b TCTCACCTTCTTTCTAACCTTTTC TCAGCAAAAATCTAGGTTTGAATC 390
Exon15 TGTAGCAAAGGGGATGAGGA CCCTAACTGCCATTGACCAT 335
Exon16 GATCTGCCTGCAAGTTCACA AAAACACAAAACTCTTTAGAGAATCAC 385
Exon17 CATCATTCAAGGCGTACTTTTG TCCCTAGACAGGATTTACATTATGA 399
Exon 17 small TAAATGGTTTTCTTTTCTCCTCCA TTCGATAAAATTGTTTCCTGTGA 233
Exon18 CTCCACATTTCAGCAACAGC GGCTGCTTCCTGAGACACA 333
Exon19 AAGTGGATGGCACCTGAAAG CCCTCAACATCTGGGTTTCT 390
Exon20 TCCATATGTCCAGTTGCATAGC GCCCAATTTGCAACCTAAGA 350
Exon21 TTCCATCAGTTAGTTGTGATCTTG GACAAAAATCATCGGCCACT 390
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sgene ID¼ENSG00000157404), using the Primer3 software (http://
www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi). Pri-
mer sequences for the 21 KIT exons and PCR product sizes are
shown in Table 2. Exons4400bp were amplified using overlapping
primer pairs. A total of 23 primers pairs were used to examine the
coding region of the KIT gene. Primers designed for exon 1 failed
to amplify under a variety of PCR conditions and were redesigned
but again failed to give a PCR product. Exon 1 was therefore not
examined. Mutations of KIT are predominantly located in exons
10, 11 and 17 (Pignon et al, 1997; Tian et al, 1999; Rubin et al,
2001; Przygodzki et al, 2002; Looijenga et al, 2003); therefore, the
tumour material was examined only at these exons. Primers
generating a smaller sized PCR fragment were designed for exons
10, 11 and 17 to allow easy amplification from paraffin-embedded
material and were specifically used to analyse the tumour material.
For constitutional DNA, all exons were examined by conforma-
tion sensitive gel electrophoresis (CSGE) (Ganguly et al, 1993).
Briefly, both PCR primers were labelled with adenosine
50[g-
32P]triphosphate by T4 polynucleotide kinase. After amplifi-
cation, PCR products were heated to 981C and cooled down to
601C over 30min to allow heteroduplex formation. PCR samples
were run on a CSGE gel (10%vv
 1 ethanediol, 13.75%vv
 1
formamide, 15%vv
 1 acrylamide with 4mgml
 1 piperazine and
1 GTB buffer (89mM Tris, 29mM taurine and 0.5mM EDTA).
Polymerase chain reaction (PCR) products from samples that
showed migration shifts on CSGE were bidirectionally sequenced
using the BigDye terminator v3 sequencing kit and a 3100
automated sequencer (Applied Biosystems, Warrington, UK).
All tumour samples were examined for exons 10, 11 and 17 of
the KIT gene by direct sequencing. The tumour material was
amplified and sequenced using specifically designed primers that
generated a smaller sized PCR fragment than those designed for
CSGE analysis and allowed for ease of amplification from tumour
material. Sequencing was performed using the BigDye terminator
v3 sequencing kit and a 3100 automated sequencer (Applied
Biosystems).
Differences in distribution between categorical variables were
assessed with the appropriate contingency table test.
RESULTS AND DISCUSSION
In total, 240 constitutional DNA samples from TGCT cases with a
positive family history were examined using CSGE. Two con-
servative nonsynonymous constitutional sequence variants were
detected, M541L and V399I (Table 3). M541L was found in 43 out
of 240 (17.9%) cases and it is a common polymorphism found in
32 out of 192 (16.6%) of normal controls. V399L was found in only
a single case and was not found in 200 controls. V399 is not
conserved in other species (mouse, zebrafish and xenopus) and the
amino-acid substitution is conservative, suggesting that this
variant is a rare polymorphism rather than a disease-causing
change. Overall, the results provide no evidence that germline KIT
mutations are associated with an increased risk of testicular
cancer.
Somatic mutations of KIT were detected in five out of 123
TGCTs examined (Table 4 and Figure 1). Three mutations involved
codon 816, a known hotspot for KIT mutations in testicular (Tian
et al, 1999; Przygodzki et al, 2002; Looijenga et al, 2003) and other
cancers (Rubin et al, 2001). Another mutation involved codon 820,
an infrequently mutated residue but one that has been previously
reported (Pignon et al, 1997). The fifth mutation was a 12bp
deletion encoding a 4 amino-acid in-frame deletion in the
cytoplasmic juxamembrane domain of KIT. In-frame deletions of
this region are common in gastrointestinal stromal tumours
(GIST) (Rubin et al, 2001) but have not been documented in
TGCT. All these mutations were shown to be somatic. Two out of
seven (28.5%) familial bilateral cases carried a somatic KIT
mutation compared with three out of 116 (2.6%) familial unilateral
cases (P¼0.026, Fisher’s exact test). Unfortunately, samples of the
other tumour/ITGCN from the two bilateral cases with KIT
Table 3 Sequence variants in KIT detected in constitutional DNA from
patients with familial TGCTs
Exon
Nucleotide
change RefSeq
NM_000222
Amino-acid
change
Number of
cases
3 G525A A168A 1
6 C999T N326N 1
7 G1216A V399I 1
10 A1642C M541L 43
10 A1659G K546K 5
16 C2370T L783L 1
17 C2451T I798I 12
18 G2607C L862L 53
19 G2643A P874P 1
Table 4 Sequence changes in KIT detected in TGCTs
Sample
name Exon
Nucleotide change RefSeq
NM_000222 Amino-acid change
Case details giving tumour type, age at diagnosis,
history of undescended testis and family history
2158-201 11 Del 1675–1686 del MYEV AA 552–555 R. sem
a and L.ITGCN
Age at diagnosis¼39 years
History of bilateral UDT
Family history¼sib pair
274-201 17 A2480G D820G L. sem
Age at diagnosis¼52 years
Family history¼MZ twins (twin brother has bilateral
disease, no tumour available for this patient)
295-304 17 G2467C D816H R. mixed and L. sem
a
Age at diagnosis¼39 and 55 years
History of UDT
Family history¼sib trio
377-1664 17 G2467T D816Y R NS
Age at diagnosis¼66 years
Family history¼father/son pair
285-201 17 G2467T D816Y L. sem
Age at diagnosis¼39 years
Family history¼sib pair
aTumour examined in bilateral cases. Sem¼Seminoma; NS¼nonseminoma; ITGCN¼intratubular germ cell neoplasia; R¼right side; L¼left side; UDT¼undescended testis.
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mutations. While the frequency of KIT mutations in unilateral
TGCT is similar to that detected previously, the proportion of
cases with bilateral disease is much lower despite the fact that we
examined a larger proportion of the KIT gene than in the study by
Looijenga et al (2003). The reason for this is unclear. However, it
may indicate that bilateral disease in the context of familial
testicular cancer has a different pathogenesis from sporadic
bilateral cases and that most of the familial bilateral cases are
explained by the elevated risk conferred by the underlying
susceptibility genes. Nevertheless, the overall pattern of an elevated
frequency of KIT mutations in bilateral compared to unilateral
cases supports the observation of Looijenga et al (2003) and
suggests that somatic KIT mutations may take place early in
development.
In conclusion, our results indicate that constitutional
mutations of KIT are not associated with a substantially
increased risk of TGCT. Somatic mutations of KIT are found in
familial TGCT tumours with a higher proportion in cases with
bilateral disease. Overall, the proportion of KIT mutations in
TGCT is low and other somatic and susceptibility genes must play
important roles.
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A       G sequence change resulting in
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Figure 1 Chromatograms showing sequence variants in KIT gene sequence in testicular tumours: (1a) exon 11 reverse sequence showing 2158-201
12bp deletion; (1b) exon 11 wild-type sequence; (2) tumour 274-201 forward (a) and reverse (b) exon 17 sequence showing A-G variant; (3) tumour
295-304 forward (a) and reverse (b) exon 17 sequence showing G-C change; (4) tumour 377-1664 forward (a) and reverse (b) exon 17 sequence
showing G-T variant; (5) tumour 285-201 forward (a) and reverse (b) exon 17 sequence showing G-T variant.
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